You are here: Industry Insights > AstraZeneca

News List

Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial worldpharmanews
May 15, 2017
AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blinded...
AstraZeneca Updates Stratos 1 Phase III Trial of Tralokinumab americanpharmaceuticalreview
May 11, 2017
AstraZeneca and MedImmune announced tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody.
AstraZeneca bounces back; gains US approval for bladder cancer drug biospectrumasia
May 08, 2017
The UK-based firm believes that the drug will become a “cornerstone” in their immuno-oncology portfolio and could generate more than $6.5 billion in global sales
AstraZeneca’s Imfinzi receives FDA accelerated approval for previously treated patients with advance cphi-online
May 05, 2017
Imfinzi is the cornerstone in an extensive immuno-oncology program across multiple cancer types and stages of disease.
AstraZeneca boosts early respiratory medicine with Pieris deal financialexpress
May 04, 2017
Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into initial Phase I clinical trials in 2017
AstraZeneca’s bladder cancer treatment receives FDA approval europeanpharmaceuticalreview
May 04, 2017
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) to treat patients with locally advanced or metastatic urothelial carcinoma (mUC).
AstraZeneca's Imfinzi Receives FDA Accelerated Approval for Previously Treated Patients with Advance americanpharmaceuticalreview
May 03, 2017
AstraZeneca and MedImmune announced the US Food and Drug Administration (FDA) granted accelerated approval to Imfinzi (durvalumab).
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridg worldpharmanews
May 03, 2017
AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC).
AstraZeneca, Heptares in Immuno-oncology Pact contractpharma
April 11, 2017
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop.
Heptares Gets $12mn AstraZeneca Milestone contractpharma
April 11, 2017
Heptares Therapeutics has achieved an important milestone in its immuno-oncology collaboration with AstraZeneca, which is focused on the development of AZD4635 (HTL-1071) as a potential new treatment for a range of cancers.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page